Results 171 to 180 of about 51,709 (292)

Movement Disorders Associated with 22q11.2 Microdeletion: A Scoping Review

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Movement disorders have recently emerged as important neurologic manifestations of the 22q11.2 microdeletion that affects nearly one in every 2000 live births. Objective We aimed to map the existing evidence regarding the spectrum, diagnosis and treatment, and etiopathogenesis of movement disorders associated with 22q11.2 ...
Nikolai Gil D. Reyes, Daniel G. Di Luca, Connie Marras, Erik Boot, Ryan K.C. Yuen, Anthony E. Lang, Anne S. Bassett   +6 more
wiley   +1 more source

Reduced striatal dopamine transmission as a transdiagnostic substrate of psychomotor retardation. [PDF]

Brain
Leong IL, Ng TH, Sen K, Burchill E, Costello H, Badenoch JB, Coebergh J, McCutcheon RA, Nair A, Browning M, Huys QJM, Lewis G, Lees A, David AS, Rogers JP.   +14 more
europepmc   +1 more source

Considerations for Initiation and Maintenance of Foslevodopa/Foscarbidopa for Advanced Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Abstract Background As Parkinson's disease (PD) progresses, motor fluctuations become increasingly difficult to manage with oral medications. Foslevodopa/foscarbidopa (LDp/CDp), delivered as a continuous 24‐h/day subcutaneous infusion, offers continuous levodopa delivery and stable plasma levodopa levels that reduce motor fluctuations. LDp/CDp has been
K. Ray Chaudhuri, Bruno Bergmans, Eric Freire‐Alvarez, Lucie Hopes, Drew S. Kern, Robert S. Kirsner, Giulia Lazzeri, Pedro Mendes‐Bastos, Noriko Nishikawa, Per Odin, Karolina Poplawska‐Domaszewicz, Rajesh Pahwa, Yuval Ramot, Klaus Seppi, Tobias Warnecke, Robert Wiggins, Megha B. Shah, Pavnit Kukreja, Bjoern Fritz, Koray Onuk, Stuart H. Isaacson   +20 more
wiley   +1 more source

Prolintane analogs as hybrid monoamine transporter ligands: Structural determinants and species differences. [PDF]

J Biol Chem
Kastner N, Islam MN, Dybek M, Roth E, Heisinger S, Holy M, Jäntsch K, Walther D, Stockner T, Baumann MH, Brandt SD, Wallach J, Sitte HH, Kudlacek O.   +13 more
europepmc   +1 more source

Budget impact of xanomeline and trospium chloride for the treatment of adults with schizophrenia in the United States. [PDF]

J Manag Care Spec Pharm
Bjerke A, Mantaian T, Gillard K, Sidovar MF, Kowalski J, Lee J, Tunnicliffe A.   +6 more
europepmc   +1 more source

Hypotensive Episodes Precede Cognitive Fluctuations in Parkinson's Disease Dementia

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Cognitive fluctuations (CFs) are a disabling feature in Parkinson's disease dementia (PDD) and contribute to caregiver burden. The relationship between CFs and neurogenic orthostatic hypotension (nOH), a common autonomic complication in PDD, has not been adequately examined.
Jorge Patino, Kevin Duque, Jesus Abanto, Aaron Bloemer, Heba Deraz, Alberto J. Espay, Abhimanyu Mahajan   +6 more
wiley   +1 more source

Neurochemical and Energetic Alterations in Depression: A Narrative Review of Potential PET Biomarkers. [PDF]

Int J Mol Sci
Cornejo Schmiedl SJ, Astudillo Ortega B, Sosa-Moscoso B, González de Armas G, Montenegro Galarza JI, Rodas JA, Leon-Rojas JE.   +6 more
europepmc   +1 more source

Exocrine Gland Dysfunction in Parkinson's Disease: Pathophysiology, Clinical Manifestations, and Therapeutic Perspectives—A Narrative Review

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Non‐motor symptoms, especially autonomic dysfunction, are major contributors to disability and decreased quality of life in Parkinson's disease (PD). Despite being common and having a wide range of clinical facets, exocrine gland dysfunction is still not well recognized and managed.
Renato P. Munhoz, Marina Farah, Laura Silveira‐Moriyama   +2 more
wiley   +1 more source

Cardiac MIBG Scintigraphy in Neurodegenerative Parkinsonism: Limitations in Clinical Practice

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Reduced cardiac uptake on 123Iodine‐metaiodobenzylguanidine (MIBG) scintigraphy is a valuable tool for differentiating neurodegenerative parkinsonism but interpretation can be difficult due to comorbidities and drug‐tracer interactions.
Frank Jagusch, Elena Redl, Christoph Theyer, Atbin Djamshidian, Alessandra Fanciulli, Werner Poewe, Philipp Mahlknecht, Beatrice Heim, Klaus Seppi, Florian Krismer   +9 more
wiley   +1 more source

Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. [PDF]

Curr Issues Mol Biol
Duarte C, Souza EB, Dias-Pinto JR, Araldi RP.   +3 more
europepmc   +1 more source